Lasting Benefit With Nivo Plus Ipi in Advanced Liver Cancer Lasting Benefit With Nivo Plus Ipi in Advanced Liver Cancer
Long-term follow-up data show a continued benefit in advanced hepatocellular carcinoma (HCC) with nivolumab and ipilimumab after disease progression on sorafenib in the Checkmate 040 trial.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 1, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Oncotarget: Prognostic biomarker for patients with hepatocellular carcinoma
(Impact Journals LLC) Reduced expression of TBX15 in tumor tissue represents a potential biomarker for predicting poor survival of patients with HCC (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 25, 2021 Category: Cancer & Oncology Source Type: news
Roche to present updated data confirming Tecentriq in combination with Avastin substantially improves overall survival in people with the most common form of liver cancer
Basel, 12 January 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) will present updated overall survival (OS) data from the Phase III IMbrave150 study evaluating Tecentriq ® (atezolizumab) in combination with Avastin® (bevacizumab), compared with sorafenib, in people with unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy. (Source: Roche Investor Update)
Source: Roche Investor Update - January 12, 2021 Category: Pharmaceuticals Source Type: news
Roche to present updated data confirming Tecentriq in combination with Avastin substantially improves overall survival in people with the most common form of liver cancer
Basel, 12 January 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) will present updated overall survival (OS) data from the Phase III IMbrave150 study evaluating Tecentriq ® (atezolizumab) in combination with Avastin® (bevacizumab), compared with sorafenib, in people with unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy. (Source: Roche Media News)
Source: Roche Media News - January 12, 2021 Category: Pharmaceuticals Source Type: news
Leaps-Bayer-leads-USD-million-Series-B-financing-Senti-Bio-develop-next-generation-therapies-using
Senti Bio’s gene circuit technology platform has the potential to optimize cell and gene therapies across delivery modalities and therapeutic areas / Proceeds to support platform expansion and advance multiple allogeneic CAR-NK cell therapy pipeline candidates for difficult-to-treat cancers, including acute myeloid leukemia and hepatocellular carcinoma (Source: Bayer Company News)
Source: Bayer Company News - January 6, 2021 Category: Pharmaceuticals Source Type: news
Liver cancer cells manipulate stromal cells involved in fibrosis to promote tumor growth
(Osaka University) Researchers led by Osaka University have found that liver cancer cells induce autophagy in hepatic stellate cells, causing them to produce a growth factor called GDF15 that promotes tumor growth. GDF15 was more highly expressed in tumor tissue than normal liver tissue, and patients with higher levels of GDF15 had a poorer prognosis. New therapies targeting GDF15 may help prevent the development and proliferation of hepatocellular carcinoma. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 6, 2021 Category: International Medicine & Public Health Source Type: news
Survival Rate for Hepatocellular Carcinoma
What Is the Survival Rate for Hepatocellular Carcinoma? (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - January 5, 2021 Category: General Medicine Source Type: news
Fibroscan Liver Stiffness After Anti-viral Treatment for HCV Fibroscan Liver Stiffness After Anti-viral Treatment for HCV
This study investigated whether liver stiffness pre- or post-anti-viral therapy is associated with the development of decompensated cirrhosis, hepatocellular carcinoma, or death.Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 16, 2020 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news
New treatment options for those with liver cancer
Sharon Silverman loves to travel. But after doctors in her hometown of Pensacola, Florida, diagnosed her with hepatocellular carcinoma and told her there were no treatment options, Sharon knew she had to take one more trip. Her destination: Mayo Clinic -- where a unique radiation procedure opened the door to future adventures. Reporter DeeDee Stiepan [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - December 2, 2020 Category: Databases & Libraries Source Type: news
Combination therapy might improve outcomes in treatment-resistant liver cancer
(Massachusetts General Hospital) A combination cancer therapy that is effective against treatment-resistant hepatocellular carcinoma (HCC) by inhibiting tumor growth and increasing survival has been identified by researchers at Massachusetts General Hospital. The dual therapy -- which combines the multikinase inhibitor drug regorafenib to " reprogram " the tumor immune microenvironment, and programmed cell death 1 antibodies to stimulate anti-tumor immunity -- improved survival in mouse models of HCC beyond what each therapy could have achieved alone. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 30, 2020 Category: Cancer & Oncology Source Type: news
Patients Cured of HCV Still at High Liver Cancer Risk Patients Cured of HCV Still at High Liver Cancer Risk
The burden of hepatocellular carcinoma (HCC) appears likely to move from patients who currently have hepatitis C virus (HCV) infection to those who have previously been cured, a new modeling study suggests.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 26, 2020 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Rural, Urban Disparities Seen for New Liver Cancer Cases
TUESDAY, Nov. 24, 2020 -- Rates of hepatocellular carcinoma (HCC) have slowed in urban areas but continue to increase in rural areas, particularly among Black and Hispanic residents, according to a study presented at The Liver Meeting, the annual... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 24, 2020 Category: Pharmaceuticals Source Type: news
Aspirin and Statins in Chronic Hepatitis B: It's Complicated Aspirin and Statins in Chronic Hepatitis B: It's Complicated
Statins play a bigger part than aspirin in reducing risk for hepatocellular carcinoma in patients with hepatitis B, new research shows, and cirrhosis seems to cancel any beneficial effect of aspirin.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 19, 2020 Category: Consumer Health News Tags: Gastroenterology News Source Type: news
Positive Data Presented on Helio Health Liver Test for the Detection of Hepatocellular Carcinoma (HCC) Advances Product Development
New data demonstrate high accuracy of blood-based cfDNA methylation test for the detection of HCC
Test has potential to outperform current screening modalities for early stage HCC within high risk populations
IRVINE, Calif., Nov. 13, 2020 -- (Healthc... Diagnostics, Oncology Helio Health, hepatocellular carcinoma (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 13, 2020 Category: Pharmaceuticals Source Type: news
EGF promotes DKK1 transcription in hepatocellular carcinoma by enhancing the phosphorylation and acetylation of histone H3
The protein Dickkopf-1 (DKK1) is frequently overexpressed at the transcript level in hepatocellular carcinoma (HCC) and promotes metastatic progression through the induction of β-catenin, a Wnt signaling effector. We investigated how DKK1 expression is induced in HCC and found that activation of the epidermal growth factor receptor (EGFR) promoted parallel MEK-ERK and PI3K-Akt pathway signaling that converged to epigenetically stimulate DKK1 transcription. In HCC cell lines stimulated with EGF, EGFR-activated ERK phosphorylated the kinase PKM2 at Ser37, which promoted its nuclear translocation. Also in these cells, EG...
Source: Signal Transduction Knowledge Environment - November 10, 2020 Category: Science Authors: Niu, J., Li, W., Liang, C., Wang, X., Yao, X., Yang, R.-H., Zhang, Z.-S., Liu, H.-F., Liu, F.-Y., Pei, S.-H., Li, W.-Q., Sun, H., Fang, D., Xie, S.-Q. Tags: STKE Research Articles Source Type: news
